Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Relapse Prevention Study in Patients With Schizophrenia

ClinicalTrials.gov ID: NCT01291511

Public ClinicalTrials.gov record NCT01291511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prevention of Relapse in Patients With Schizophrenia Receiving Either Flexible Dose Iloperidone or Placebo in Long-term Use (up to 26 Weeks) Followed by up to 52 Weeks of Open-label Extension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia

Study identification

NCT ID
NCT01291511
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Vanda Pharmaceuticals
Industry
Enrollment
635 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2011
Primary completion
Feb 28, 2014
Completion
Feb 28, 2015
Last update posted
Jul 16, 2023

2011 – 2015

United States locations

U.S. sites
28
U.S. states
12
U.S. cities
25
Facility City State ZIP Site status
Vanda Investigative Site Anaheim California 92604
Vanda Investigative Site Bellflower California 92706
Vanda Investigative Site Costa Mesa California 92626
Vanda Investigative Site Escondido California 92025
Vanda Investigative Site La Habra California 90631
Vanda Investigative Site Oceanside California 92056
Vanda Investigative Site Orange California 92868
Vanda Investigative Site Pico Rivera California 90660
Vanda Investigative Site Riverside California 92506
Vanda Investigative Site San Diego California 92102
Vanda Investigative Site San Diego California 92103
Vanda Investigative Site San Diego California 92121
Vanda Investigative Site Santa Ana California 92705
Vanda Investigative Site Melbourne Florida 32901
Vanda Investigative Site Miami Florida 33126
Vanda Investigative Site Oakland Park Florida 33334
Vanda Investigative Site Atlanta Georgia 30308
Vanda Investigative Site Atlanta Georgia 30328
Vanda Investigative Site St Louis Missouri 63109
Vanda Investigative Site Nashua New Hampshire 03060
Vanda Investigative Site Marlton New Jersey 08053
Vanda Investigative Site Brooklyn New York 11235
Vanda Investigative Site Staten Island New York 10312
Vanda Investigative Site Hickory North Carolina 28601
Vanda Investigative Site Beachwood Ohio 44122
Vanda Investigative Site Philadelphia Pennsylvania 19139
Vanda Investigative Site Irving Texas 75062
Vanda Investigative Site Salt Lake City Utah 84106

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 35 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01291511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 16, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01291511 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →